Insomnia Treatment: What Research Shows About CBT-I and Sleep Interventions

Insomnia disorder, characterized by difficulty falling asleep, staying asleep, or waking too early despite adequate opportunity for sleep, affects approximately 10 to 15 percent of adults and is one of the most common complaints in primary care settings. Chronic insomnia is associated with significant impairment in daytime functioning including fatigue, cognitive difficulties, mood disturbance, and reduced quality of life, and with increased risk of depression, anxiety, and cardiovascular disease. Despite its prevalence and consequences, insomnia is frequently undertreated or managed with approaches that research does not support as first-line care. Cognitive-behavioral therapy for insomnia, known as CBT-I, is the treatment with the strongest evidence base for chronic insomnia and is recommended as first-line treatment by major clinical guidelines including the American College of Physicians. CBT-I addresses the thoughts and behaviors that perpetuate insomnia rather than simply targeting the symptom of sleeplessness. The treatment typically includes sleep restriction, which consolidates sleep into a more compressed window to increase sleep drive; stimulus control, which involves associating the bed with sleepiness rather than wakefulness; relaxation techniques; and cognitive restructuring that addresses catastrophic thoughts about sleep and its consequences. Research on CBT-I effectiveness is extensive and consistently positive. Meta-analyses of CBT-I trials find large effects on sleep onset latency, time awake after sleep onset, and total sleep time, with effects that are maintained at long-term follow-up of one to two years. Crucially, research comparing CBT-I to sleep medication finds that while medication produces faster initial improvement, CBT-I produces superior outcomes at longer follow-up because the skills learned in treatment continue to benefit sleep after treatment ends, while medication effects reverse when stopped. This durability advantage of CBT-I is one of the strongest arguments for it as first-line treatment. Pharmacological treatment of insomnia has evolved as research on long-term outcomes has accumulated. Benzodiazepines, once commonly prescribed, are associated with tolerance, dependence, cognitive impairment, and increased fall risk in older adults, and clinical guidelines now discourage their use as first-line treatment. Non-benzodiazepine hypnotics are more commonly used but also carry risks of next-day sedation and other side effects. Newer agents targeting orexin pathways have been approved and show a different side effect profile, though long-term outcome data is less extensive than for CBT-I. Research consistently finds that medication should be considered as a short-term adjunct to CBT-I rather than as a standalone long-term treatment. Access to CBT-I is limited by the shortage of trained therapists, the structure of mental health care delivery, and insurance coverage. CBT-I is typically delivered in 6 to 8 weekly sessions with a trained therapist, which requires access to a psychologist or other provider with specific training in the protocol. Given this access barrier, digital CBT-I programs delivered through apps and online platforms have been developed and evaluated. Research on digital CBT-I finds significant improvements in sleep outcomes comparable to those achieved with therapist-delivered treatment in some randomized trials, making digital delivery an important strategy for expanding access to effective insomnia treatment. Brief behavioral treatment for insomnia, which condenses the core behavioral components of CBT-I into two sessions, has been evaluated as a more accessible alternative for primary care settings. Research on abbreviated behavioral treatment finds significant improvements in sleep outcomes with a smaller therapist time investment, suggesting that the behavioral components of CBT-I may be deliverable in settings where the full protocol is not feasible. Integration of CBT-I delivery into primary care through collaborative care models is being studied as a strategy for reaching the large population of insomnia sufferers who never access specialty mental health care. Insomnia comorbid with other conditions presents specific challenges. Research finds that insomnia is highly comorbid with depression, anxiety, chronic pain, and other medical conditions, and that treating the comorbid condition alone does not reliably resolve insomnia. Insomnia was historically conceptualized as a symptom of other conditions rather than a disorder in its own right, and this secondary status shaped treatment approaches. Research supporting bidirectional relationships between insomnia and its comorbidities, in which each condition worsens the other, has shifted clinical thinking toward treating insomnia directly rather than waiting for it to resolve with treatment of the primary condition.